Literature DB >> 35607807

Targeting Necroptosis as a Promising Therapy for Alzheimer's Disease.

Wenli Zhao1, Yue Liu2, Lijuan Xu1,2, Yuan He3, Zhenyu Cai1,3, Jianqiang Yu1, Wannian Zhang1,2, Chengguo Xing4, Chunlin Zhuang1,2, Zhuo Qu1.   

Abstract

Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder featured by memory loss and cognitive default. However, there has been no effective therapeutic approach to prevent the development of AD and the available therapies are only to alleviate some symptoms with limited efficacy and severe side effects. Necroptosis is a new kind of cell death, being regarded as a genetically programmed and regulated pattern of necrosis. Increasing evidence reveals that necroptosis is tightly related to the occurrence and development of AD. This review aims to summarize the potential role of necroptosis in AD progression and the therapeutic capacity of targeting necroptosis for AD patients.

Entities:  

Keywords:  Alzheimer’s disease; MLKL; RIPK1; RIPK3; necroptosis; therapy

Mesh:

Substances:

Year:  2022        PMID: 35607807     DOI: 10.1021/acschemneuro.2c00172

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   5.780


  1 in total

1.  A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma.

Authors:  Zilu Meng; Wenhan Yang; Lei Zhu; Wanyu Liu; Yudong Wang
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.